The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone

British Journal of Pharmacology

Volumn 160, Issue 4, 2010, Pages 907-918

  Samer, C F ^a,b   Daali, Y ^b,c   Wagner, M ^c   Hopfgartner, G ^c   Eap, C B ^a,c   Rebsamen, M C ^c   Rossier, M F ^c   Hochstrasser, D ^c   Dayer, P ^b,c   Desmeules, J A ^b,c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

CYP2D6; CYP3A; Drug drug interactions; Oxycodone; Oxymorphone; Pharmacokinetics; Phenotypes

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DRUG METABOLITE; KETOCONAZOLE; MIDAZOLAM; NALOXONE; NOROXYCODONE; NOROXYMORPHONE; OXYCODONE; OXYMORPHONE; PLACEBO; QUINIDINE; UNCLASSIFIED DRUG; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 3A INHIBITOR; ENZYME INHIBITOR; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RELEASE; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IMMEDIATE DRUG RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; BLOOD; CHEMISTRY; DRUG DETOXIFICATION; DRUG INTERACTION; GENETICS; METABOLISM; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2D6 INHIBITORS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; GENOTYPE; HUMANS; KETOCONAZOLE; MALE; METABOLIC DETOXICATION, PHASE I; OXYCODONE; PHENOTYPE; POLYMORPHISM, GENETIC; QUINIDINE; RECEPTORS, OPIOID, MU; YOUNG ADULT;

EID: 77952808783     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00673.x     Document Type: Article

References (27)

1. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Backlund M, Lindgren L, Kajimoto Y, Rosenberg PH (1997). Comparison of epidural morphine and oxycodone for pain after abdominal surgery. J Clin Anesth 9 : 30 35.
3. Caraco Y, Sheller J, Wood AJ (1996). Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 278 : 1165 1174.
4. Chen ZR, Irvine RJ, Somogyi AA, Bochner F (1991). Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 48 : 2165 2171.
5. Cleary J, Mikus G, Somogyi A, Bochner F (1994). The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther 271 : 1528 1534.
6. Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW (1983). Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 11 : 446 450.
7. Daali Y, Cherkaoui S, Doffey-Lazeyras F, Dayer P, Desmeules JA (2008). Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. J Chromatogr B Analyt Technol Biomed Life Sci 861 : 56 63.
8. Dayer P, Desmeules J, Leemann T, Striberni R (1988). Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochemical Biophysical Res Comms 152 : 411 416.
9. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G et al. (2004). Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60 : 237 246.
10. Falk E (1917). Eukodal ein neues Narkoticum. Muenchener Medizinische Wochenschrift 20 : 381 384.
11. Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF et al. (2007). Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 81 : 242 251.
12. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P et al. (2004). Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351 : 2827 2831.
13. Hagelberg NM, Nieminen TH, Saari TI, Neuvonen M, Neuvonen PJ, Laine K et al. (2009). Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65 : 263 271.
14. Heiskanen T, Olkkola KT, Kalso E (1998). Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64 : 603 611.
15. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD (1996). Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59 : 52 61.
16. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006). Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79 : 461 479.
17. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004). Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32 : 447 454.
18. Lee HK, Lewis LD, Tsongalis GJ, Mcmullin M, Schur BC, Wong SH et al. (2006). Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 367 : 196 200.
19. Lemberg K, Kontinen VK, Viljakka K, Kylanlahti I, Yli-Kauhaluoma J, Kalso E (2006). Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth Analg 102 : 1768 1774.
20. Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR (1996). Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 42 : 747 756.
21. Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K et al. (2009). Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110 : 1371 1378.
22. Poyhia R, Vainio A, Kalso E (1993). A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8 : 63 67.
23. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C et al. (2009). The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 9 : 34 41.
24. Samer CF, Desmeules JA, Dayer P (2006). Individualizing analgesic prescription part I: pharmacogenetics of opioid analgesics. Personalized Medicine 3 : 239 269.
25. Samer CF, Piguet V, Dayer P, Desmeules JA (2005). Genetic polymorphism and drug interactions: their importance in the treatment of pain. Can J Anesth 52 : 806 821.
26. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC et al. (2010). Genetic polymorphism and drug interactions modulating CYP2D6 and CYP3A activities have a major impact on oxycodone analgesic efficacy and safety. Br J Pharmacol 160 : 919 930.
27. Tyndale RF, Droll KP, Sellers EM (1997). Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 7 : 375 379.